CRISPR Therapeutics AG (NASDAQ:CRSP) and Kodiak Sciences Inc. (NASDAQ:KOD) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||64||0.00||35.65M||-0.46||0.00|
|Kodiak Sciences Inc.||67||-4.18||15.04M||-1.25||0.00|
Demonstrates CRISPR Therapeutics AG and Kodiak Sciences Inc. earnings per share (EPS), gross revenue and valuation.
Table 2 has CRISPR Therapeutics AG and Kodiak Sciences Inc.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||55,503,658.73%||-2.6%||-2%|
|Kodiak Sciences Inc.||22,501,496.11%||-62.6%||-56.9%|
The current Quick Ratio of CRISPR Therapeutics AG is 8.3 while its Current Ratio is 8.3. Meanwhile, Kodiak Sciences Inc. has a Current Ratio of 8.4 while its Quick Ratio is 8.4. Kodiak Sciences Inc. is better positioned to pay off its short-term and long-term debts than CRISPR Therapeutics AG.
Recommendations and Ratings for CRISPR Therapeutics AG and Kodiak Sciences Inc. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
|Kodiak Sciences Inc.||0||0||3||3.00|
$72 is CRISPR Therapeutics AG’s consensus price target while its potential upside is 23.31%. On the other hand, Kodiak Sciences Inc.’s potential upside is 37.29% and its consensus price target is $88. The data from earlier shows that analysts opinion suggest that Kodiak Sciences Inc. seems more appealing than CRISPR Therapeutics AG.
Insider & Institutional Ownership
Roughly 46.8% of CRISPR Therapeutics AG shares are owned by institutional investors while 68.6% of Kodiak Sciences Inc. are owned by institutional investors. About 0.4% of CRISPR Therapeutics AG’s share are owned by insiders. Competitively, 20.07% are Kodiak Sciences Inc.’s share owned by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
|Kodiak Sciences Inc.||117.8%||196.55%||437.25%||455.78%||593.23%||808.03%|
For the past year CRISPR Therapeutics AG’s stock price has smaller growth than Kodiak Sciences Inc.
CRISPR Therapeutics AG beats Kodiak Sciences Inc. on 7 of the 11 factors.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.